Genmab
GMAB
212 hedge funds and large institutions have $1.89B invested in Genmab in 2021 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 83 increasing their positions, 55 reducing their positions, and 39 closing their positions.
96% more call options, than puts
Call options by funds: $5.96M | Put options by funds: $3.04M
51% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 55
38% more capital invested
Capital invested by funds: $1.37B → $1.89B (+$520M)
10% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 39
6.6% more ownership
Funds ownership: 63.76% → 70.37% (+6.6%)
1% more funds holding
Funds holding: 209 → 212 (+3)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$160M |
| 2 |
BlackRock
New York
|
+$134M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$26.4M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$18.5M |
| 5 |
HJGA
Hardman Johnston Global Advisors
Stamford,
Connecticut
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$8.72M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$8.45M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$8.08M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$7.91M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$5.68M |
GMAB Hedge Fund Activity: Q2 2021 in Review
212 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q2 2021, worth a combined $1.89B — up 38% from $1.37B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new GMAB positions and 39 closed out — a net gain of 4 holders — while 83 added to existing stakes and 55 trimmed.
The largest buyer was Macquarie Group, opening a new position worth an estimated $160M. The largest seller was HHLR Advisors, exiting entirely with an estimated $8.72M sold.
- 212 institutional investors held Genmab (GMAB) as of Q2 2021, up from 209 in Q1 2021.
- Funds reported $1.89B of Genmab stock for Q2 2021, up 38% quarter-over-quarter.
- 43 funds opened new Genmab positions in Q2 2021 and 39 closed out, a net change of +4 holders.
- The largest Genmab buyer in Q2 2021 was Macquarie Group, an estimated $160M added.
- The largest Genmab seller in Q2 2021 was HHLR Advisors, an estimated $8.72M sold.
Based on aggregated 13F filings for Q2 2021.